Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Elicera receives funding for clinical trials with ELC-301

Gene therapy company Elicera Therapeutics has been awarded 2.5 million Euros in funding from the European Innovation Council (EIC) Accelerator Programme. The grant is great news for the company, which now has sufficient funds to conduct Elicera's planned clinical phase I/II study evaluating its CAR T-cell therapy ELC-301 in the treatment of B-cell lymphoma.Read the full article at biostock.se: https://www.biostock.se/en/2022/06/elicera-erhaller-finansiering-for-kliniska-studier-med-elc-301/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Abliva secures funding to advance KL1333 into phase II/III

It has undeniably been an eventful week for Swedish biotech Abliva. On Tuesday, the company, whose focus is primary mitochondrial diseases, announced that they are conducting a 200 MSEK financing round. The bulk of the raised capital will be used to finance the upcoming registrational phase II/III trial with lead candidate KL1333.Read the full article at biostock.se: https://www.biostock.se/en/2022/06/abliva-secures-funding-to-advance-kl1333-into-phase-ii-iii/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

DEVERSIFY SELECTED FOR EIT HEALTH’S BRIDGEHEAD PROGRAMME 2022

Deversify AB is a Swedish health tech company offering solutions for improved individual health and wellbeing. The company has been handpicked as one of 29 start-ups and scale-ups to participate in the prestigious Bridgehead Programme. Bridgehead serves to support promising health companies in gaining crucial connections and experience through EIT Health’s vast and diverse network. ”Bridgehead is a dream opportunity for us to build presence in more European countries and ultimately, through this impressive network, to improve health beyond any borders. We are particularly proud to

Photocure ASA: Exercise of employee share options

Oslo, Norway, 3 June 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 1 June 2022 regarding exercise of share options.The price for option shares sold by the primary insiders, has been determined at a price of NOK 102.072 per share. The primary insiders having exercised options has used the net proceeds from the sale of option shares to purchase shares in Photocure at a price per share of NOK 102.072 as follows: · Dan Schneider, President and CEO, has purchased 29,435 shares · Erik Dahl, CFO, has purchased 5,887

Latour acquires Barcol-Air

Investment AB Latour has, through its wholly-owned subsidiary Swegon Group AB, acquired Barcol-Air, a leading supplier of radiant ceiling systems. The company was founded in 1979 and has 90 employees, with the head office in Schwerzenbach, Switzerland and production located in St. Leon-Rot, Germany. Net sales in 2021 amounted to EUR 37,2 million. The acquisition of Barcol-Air means that Swegon continue to build on its already strong position within radiant ceilings, with the existing Zent-Frenger business. The acquisition makes it possible to go from being a strong player in Germany to

Photocure ASA: Acquisition of own shares under the share buy-back program for incentive scheme

Oslo, Norway, 3 June 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 1 June 2022 regarding initiation of a share buyback program.The Company has completed its share buyback program. The Company has acquired a total of 36,000 own shares at a price per share of NOK 102.072. A report of all the transactions relating to the buy-back programme, in a detailed form and in an aggregated form is attached. The shares acquired is used for the Company's incentive scheme and sold to employees. After the acquisition and sale to

Raytelligence signs agreements with Careteq for Malaysia and Singapore

Raytelligence expands its dealership agreement with Careteq, Australia to include the Malaysia and Singapore markets. A dealership agreement has previously been signed for Australia, New Zealand, the USA and Canada. Careteq, https://www.careteq.com.au/  is a listed company on the Australian Securities Exchange (ASX) "Malaysia and Singapore are very large markets in e-health and this investment shows that Careteq strongly believes in our product Eazense," says the Companys CEO Pelle Viberg.   For questions Peter Martinson, CFO peter@raytelligence.com +46 708-14 64 65

BioStock: Curasight starts 2022 off strong

It is safe to say that Q1 was eventful for Danish Curasight who expanded its clinical development portfolio with no fewer than two new indications. With a solid financial position and late-stage clinical development in four different cancer indications, the company sets itself up for quite an interesting year. BioStock contacted Curasight’s CEO Ulrich Krasilnikoff to get his view on the past quarter.Read the full article at biostock.se:https://www.biostock.se/en/2022/06/curasight-starts-2022-off-strongThis is a press release from BioStock - Connecting Innovation & Capital. https://www.

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 2nd June 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 27,994,091 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Netmore's network infrastructure company ECN acquires the Dutch LoRaWAN operator Techtenna

The network infrastructure company European Connectivity Networks (ECN), which is jointly owned by Netmore Group and the infrastructure company Polar Structure, acquires the Dutch LoRaWAN operator Techtenna. The deal covers both network infrastructure and existing customer agreements, and is expected to contribute to significant sensor growth in the IoT network in the coming years."The acquisition of Techtenna is an important step for our European IoT expansion. We enable the conditions to easily and cost-effectively connect smart meters and sensors that provide conditions for measurability

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release June 3, 2022 at 09:20 a.m. Nokian Tyres has received an announcement from JPMorgan Chase & Co. on June 1, 2022, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. The reason for the announcement is that the total holding in Nokian Tyres shares owned by J.P. Morgan SE, subsidiary of JPMorgan Chase & Co., exceeded the level of 5% of the share capital in Nokian Tyres plc, as a result of intra-group transactions concluded on May 31, 2022. JPMorgan Chase & Co. held on deal date a total of 10,414,581 Nokian Tyres’ shares

Sectra’s year-end report 2021/2022: Higher sales and profit for the fiscal year—Board of Directors proposes increased dividend

Press release – Linköping, June 3, 2022 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) posted its highest sales to date, growth in recurring revenue and increased profit compared with the comparative year. This financial performance was a result of the company’s efforts to assist customers in providing the best possible care and increasing cybersecurity in areas where society’s critical functions are the most vulnerable. Customers’ need for Sectra’s offerings was confirmed by the fact that order bookings surpassed SEK 1 billion

PharmNovo raises SEK 67 million to take neuropathic pain drug candidate into clinical trial

PharmNovo AB, a Swedish pharmaceutical company developing drugs for neuropathic pain, so-called nerve pain, has completed a share issue of SEK 67 million led by the investor syndicate Sciety. Karolinska Development AB also participated in the share issue. The capital will be used to produce the drug substance, implement a clinical phase I study, and continue the company's development.Nerve pain affects almost ten percent of the population in Europe and the United States and significantly impairs people's quality of life. The drug candidate PN6047 from PharmNovo is an entirely new type of

Veidekke: To renovate PostNord’s headquarters in Solna, Stockholm

Veidekke's subsidiary Arcona has been commissioned by Ursus Real Estate Management AS to renovate 14,300 m[2] of office area currently leased by PostNord in the Arken building in Solna. Work on the tenant adaptation project started in December 2021 and is scheduled for completion by the end of 2022. The collaborative design and build contract has a value of approx. SEK 117 million.PostNord has signed a new lease agreement for their head offices in the building with Arken’s owners Ursus. The property will be converted into a multi-tenant building, in which PostNord will occupy the top three

Kamux Oyj - Managers' Transactions

Kamux Corporation, Managers’ Transactions, 3.6.2022 at 09:00 Kamux Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Jaana Viertola Position: Member of the Board/Deputy member Issuer: Kamux Oyj LEI: 743700KCVYIYNLPZYN56 Notification type: INITIAL NOTIFICATION Reference number: 15811/6/6 ____________________________________________ Transaction date: 2022-06-02 Venue not applicable Instrument type: SHARE ISIN: FI4000206750 Nature of the transaction: RECEIPT OF A SHARE-

Aiforia Technologies Plc – Managers’ Transactions

Aiforia Technologies Plc COMPANY RELEASE, MANAGERS’ TRANSACTIONS 3 June 2022 09.00 a.m. EEST___________________________________________________________   Person subject to the notification requirement Name: Jukka Tapaninen Position: Chief Executive Officer   Issuer: Aiforia Technologies Oyj LEI: 743700TJRVBX7420Y723 Notification type: INITIAL NOTIFICATION Reference number: 15792/5/6 ___________________________________________________________   Transaction date: 2022-05-31 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE

Scandinavian ChemoTech receives a new patent on the Japanese market

Scandinavian ChemoTech has been notified that the patent authority in Japan has approved the Company's patent relating to the unique IQwave™, vetIQure™, probe and the unique electrodes that the TSE™ treatment kit consists of.The approved patent protects both the unique probe, which the doctor and veterinarian hold, as well as the unique electrodes (needles) that are used to deliver the dynamic and tumour specific pulse in the treatment of patients.   The probe has unique properties that allow you to adjust how large an area you want to treat. Because the electrodes can be attached in

Peab builds tenant-owner apartments in Norrköping

Peab has been commissioned to build 46 tenant-owner apartments in Inre Hamnen in Norrköping. The customer is Riksbyggen and the contract is worth SEK 103 million.In a newly built block, with focus on sustainability, located in Inre Hamnen in Norrköping Peab is building 46 one to five rooms and a kitchen, tenant-owner apartments to Riksbyggen. Four of the 46 apartments in Brf Kronomagasinet will be in townhouse style. There will be a terrace, greenhouse and cultivation areas on the roof. The building will be constructed in wood with a variated brick facade so that it will blend in with the

Terveystalo expands its domestic commercial paper program

Terveystalo Plc, Stock Exchange Release, 3 June 2022 at 09:00 am EEST  Terveystalo expands the EUR 100 million bilateral commercial paper program signed in February 2022 to a EUR 200 million multi-bank program. Under the program, the company may issue commercial papers with a maturity of less than one year.  The financing arrangement diversifies Terveystalo' s financing base and supports the Group's normal working capital financing.  The commercial paper program is organized by OP Corporate Bank Plc, Nordea Bank Plc, the Helsinki branch of Skandinaviska Enskilda Banken AB (publ)

Valmet chosen again as the third most attractive employer by the engineering students in Finland

Valmet Oyj’s press release on June 3, 2022 at 9:00 a.m. EESTValmet has been chosen as the third most attractive employer by engineering students in Finland for the second year in a row. The ranking was published in Universum’s annual Talent Research, which is the biggest employer survey in Finland. In recent years, Valmet has been actively developing its student and university collaboration in Finland and abroad. The focus has been on developing new trainee programs, establishing a global concept for university cooperation, collaborating with schools to make engineering as a subject more

CEO Andreas Ternström leaves the Group

The CEO and President Andreas Ternström, working in the company since 2016, has in collaboration with the Board of Directors, decided to end his employment with the company and will today do his last day of work as CEO of Scout Gaming Group. The Board has appointed CFO Niklas Jönsson as the acting CEO during the time for the recruitment of a new CEO. Scout Gaming Groups newly appointed Chairman of the Board Niklas Braathen comments: "I want on behalf of the company give a big appreciation to Andreas who has who put in a very great commitment to creating Scout Gaming’s organization and

Vicore amends primary endpoint to accelerate the Phase 3 trial in COVID-19 patients

· Based on the profile of C21 and emerging COVID-19 data, the ongoing Phase 3 trial has been amended to revise the primary endpoint and reduce sample size · The amendment has been adopted to reflect the current SARS-CoV-2 virus landscape and will accelerate study completion · Expected read-out during Q3 2022 Gothenburg, June 3, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces an amendment of the ongoing COVID-19 Phase 3 trial (ATTRACT-3). In

Notice to EAB Group Plc’s Extraordinary General Meeting

EAB Group Plc, Stock Exchange Release, 3 June 2022, 9:00 a.m. (EET)   Notice to EAB Group Plc’s Extraordinary General Meeting   EAB Group Plc’s (“EAB” or the “Company”) shareholders are invited to the Extraordinary General Meeting to be held on Thursday 14 July 2022 at 2 p.m. EEST at Borenius Attorneys’ premises at Eteläesplanadi 2, Helsinki. The reception of participants enrolled to the meeting will begin at 1:30 p.m. EEST.   A. ITEMS ON THE AGENDA OF THE EXTRAORDINARY GENERAL MEETING   At the Extraordinary General Meeting, the following matters will be considered:

Spinnova Plc: Chief Product Officer Lotta Kopra has resigned from her operative role – continues as an Advisor

SPINNOVA PLC, COMPANY RELEASE 3 June 2022, 8:45 a.m. EEST Spinnova Plc: Chief Product Officer Lotta Kopra has resigned from her operative role – continues as an Advisor Lotta Kopra has resigned from her operative role as the Chief Product Officer and the Management Team member. She will continue to support the management and the growth of the company in the role of an Advisor to the company.  Her operative responsibilities and tasks will be transferred to other Management Team members until a new person has been appointed. Spinnova Plc For further information, please contact:

There are no items matching the current filter
There are no more items matching the current filter
Back to top